DEEPULL
DeepUll is a biotech company that focuses its activity on the development of a new diagnostic system for early-stage sepsis condition. DeepUll’s proposal is based on quickly identifying the pathogens and offering the antibiogram within a few hours on the one hand, and on using the data and learning about the patient’s immunological and functional status on the other. The system allows doctors to predict the future appearance and evolution of sepsis within a short period of time and thus provide a suitable clinical response even before the symptoms arise.
DEEPULL
Industry:
Biotechnology Life Science
Founded:
2019-01-01
Address:
Barcelona, Catalonia, Spain
Country:
Spain
Total Employee:
1+
Status:
Active
Total Funding:
3.5 M EUR
Similar Organizations
Axcella
Axcella is a biotechnology company that treats diseases using endogenous metabolic modulators.
Bright Peak Therapeutics
Bright Peak is a biotech company that develops a portfolio of immunotherapies for the treatment of cancer and autoimmune diseases.
Demetrix
Demetrix is a biotechnology company dedicated to researching and producing bioactive ingredients.
Novellus
Novellus is a biotechnology company working to develop engineered cellular medicines.
RNAimmune
RNAimmune is a biopharmaceutical company specializing in the discovery and development of mRNA-based therapeutics and vaccines.
Current Employees Featured
Founder
Investors List
Alta Life Sciences
Alta Life Sciences investment in Series A - DeepUll
Kurma Partners
Kurma Partners investment in Series A - DeepUll
More informations about "DeepUll"
Deepull
Furthermore, confirming and identifying the underlying infection is a complicated and time-consuming task for the hospital laboratory. The need for faster, more sensitive diagnostic technology has been a recognized unmet medical need for decades. This is the challenge that …See details»
DeepUll - Crunchbase Company Profile & Funding
DeepUll is a biotech company that focuses its activity on the development of a new diagnostic system for early-stage sepsis condition.See details»
DeepUll Company Profile 2024: Valuation, Funding
Information on valuation, funding, cap tables, investors, and executives for DeepUll. Use the PitchBook Platform to explore the full profile.See details»
deepull - LinkedIn
Deepull Biotechnology Research deepull is a development-stage clinical diagnostics company focusing on direct from blood sepsis diagnostics.See details»
DeepUll - Funding, Financials, Valuation & Investors
DeepUll is a biotech company that focuses its activity on the development of a new diagnostic system for early-stage sepsis condition.See details»
Spain: €20 million EIB loan to DeepUll accelerates early …
Dec 13, 2022 The European Investment Bank (EIB) is providing DeepUll, a medical diagnostics company developing culture-free, affordable diagnostic solutions for the early identification of sepsis and other acute infections, with a …See details»
DeepUll - Updates, News, Events, Signals & Triggers
DeepUll is a biotech company that focuses its activity on the development of a new diagnostic system for early-stage sepsis condition.See details»
DeepUll Company Profile - Office Locations, Competitors, Revenue ...
DeepUll has 5 employees at their 1 location and $16.7 m in total funding,. See insights on DeepUll including office locations, competitors, revenue, financials, executives, subsidiaries and more …See details»
Sepsis Testing Startup DeepUll Raises €13M | GenomeWeb
Oct 20, 2022 DeepUll was founded two years ago by Carrera and Rafel Bru, the cofounders of Stat-Dx. That company offered a multiplex platform for infectious disease testing and was …See details»
DeepUll Raises $13 Million in Series B - The SaaS News
Oct 24, 2022 DeepUll, a Barcelona, Spain-based medical diagnostics company, announced that it raised €13 million in a Series B round of funding. The round was led by new investors …See details»
Spain-based DeepUll raises €13M to advance it early sepsis …
Barcelona-based DeepUll, a medical diagnostics company has raised €13M in a Series B round of funding led by Innvierte.See details»
deepull receives FDA Breakthrough Device Designation for its …
Dec 5, 2024 deepull, a medical device company developing culture-free diagnostic solutions for rapid pathogen identification, announced today that it has received Breakthrough Device …See details»
FDA grants breakthrough device designation to deepull’s BSI test
Dec 2, 2024 The US Food and Drug Administration (FDA) has granted breakthrough device designation to deepull’s UllCORE bloodstream infection (BSI) test. The test, which provides …See details»
deepull receives FDA Breakthrough Device Designation for
Dec 2, 2024 Jordi Carrera, Chief Executive Officer and Co-Founder of deepull, said: “We are thrilled to receive breakthrough designation from the FDA.See details»
☑️deepull — Consulting Organization from Spain — Health sector
About deepull is a development-stage clinical diagnostics company focusing on direct from blood sepsis diagnostics. We are based in Barcelona, Spain.See details»
Deepull - Asabys Partners
DeepUll is a medical diagnostics company developing culture-free diagnostic solutions for sepsis and acute infections. Founded in 2020 in Barcelona by the founders of STAT-Dx (sold to …See details»
FDA grants breakthrough device designation to DeepUll's …
Dec 4, 2024 Diagnostics developer DeepUll has received breakthrough device designation from the U.S. Food and Drug Administration (FDA) for its rapid bloodstream infection test. The …See details»
DeepUll - Contacts, Employees, Board Members, Advisors & Alumni
DeepUll is a biotech company that focuses its activity on the development of a new diagnostic system for early-stage sepsis condition.See details»
Meyer leads DePaul against St. John's after 23-point performance
2 days ago DePaul visits the St. John's Red Storm after Jacob Meyer scored 23 points in the Blue Demons' 91-72 win against the Wichita State Shockers.See details»
Series B - DeepUll - 2023-03-01 - Crunchbase Funding Round Profile
Mar 1, 2023 Asabys Partners - Investing across the board in human healthcare — Sabadell Asabys invests in DeepUll extending its Series B to €17MSee details»